1: Fu JN, Li J, Tan Q, Yin HW, Xiong K, Wang TY, Ren XY, Zeng HH. Thioredxin
reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer 
cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M 
phase arrest. Invest New Drugs. 2010 Mar 2. [Epub ahead of print] PubMed PMID:
20195699.

2: Tan Q, Ren XY, Li J, Wang F, Deng SJ, Zeng HH. [Correlation of plasma
thioredoxin reductase activity to growth of H22 hepatocellular carcinoma
xenografts in Kunming mice.]. Chin J Cancer. 2009 May;28(5):472-7. Chinese.
PubMed PMID: 19624873.

3: Tan Q, Li J, Yin HW, Wang LH, Tang WC, Zhao F, Liu XM, Zeng HH. Augmented
antitumor effects of combination therapy of cisplatin with ethaselen as a novel
thioredoxin reductase inhibitor on human A549 cell in vivo. Invest New Drugs.
2009 Mar 7. [Epub ahead of print] PubMed PMID: 19271154.

4: Thompson RB, Zeng HH, Ohnemus D, McCranor B, Cramer M, Moffett J.
Instrumentation for fluorescence-based fiber optic biosensors. Methods Enzymol.
2008;450:311-37. Review. PubMed PMID: 19152867.

5: Chen HP, Zhang L, Xu BH, Kang LM, Yang SL, Zeng HH, Shi XY. Nitric oxide
stimulates embryonic somatotroph differentiation and growth hormone mRNA and
protein expression through a cyclic guanosine monophosphate-independent
mechanism. Tissue Cell. 2009 Apr;41(2):133-40. Epub 2008 Nov 18. PubMed PMID:
19019400.

6: Zeng HH, Li ZG, Wu MY. [Subjectively assessed quality of life in long-term
survivors among patients with childhood acute lymphoblastic leukemia]. Zhonghua
Er Ke Za Zhi. 2007 Nov;45(11):867-9. Chinese. PubMed PMID: 18282426.

7: Peng ZF, Lan LX, Zhao F, Li J, Tan Q, Yin HW, Zeng HH. A novel thioredoxin
reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 
cells. J Zhejiang Univ Sci B. 2008 Jan;9(1):16-21. PubMed PMID: 18196608; PubMed 
Central PMCID: PMC2170464.